Abstract
Analysis assessed the post-marketing reporting rates for adverse drug reactions (ADRs) in patients treated with parenteral on-demand hereditary angioedema (HAE) drugs utilizing the FDA’s Adverse Event Reporting System (FAERS).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
